

04-26-02

9P1614

#5

# AMSTER, ROTHSTEIN & EBENSTEIN

ATTORNEYS AT LAW

PATENTS • TRADEMARKS • COPYRIGHTS

90 PARK AVENUE

NEW YORK, NEW YORK 10016

TELEPHONE: (212) 697-5995

FACSIMILE: (212) 286-0854

NEAL L. ROSENBERG  
DENISE A. LINDENAUER  
NANCY M. DODDERIDGE  
PATRICK BOLAND  
TREBOR LLOYD  
JOSEPH M. CASINO  
JOHN S. ECONOMOU  
MICHAEL V. SOLOMITA  
HOLLY PEKOWSKY  
MICHAEL P. KENNEY  
MARION P. METELSKI  
MONIQUE L. RIBANDO

RECEIVED  
APR 24 2002  
TECH. COMM. DIV.  
U.S. PAT. & TM. OFF.  
WASHINGTON, D.C.  
ADMITTED IN NEW YORK

April 24, 2002

## via Express Mail

Assistant Commissioner for Patents  
Washington, DC 20231

"Express Mail" mailing label No. EV 034639866 US

Date of Deposit: April 24, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Name: Elie H. Gendloff

Signature:

Re: U.S. Patent Application Serial No. 10/038,760 - Small Entity Status  
Title: INHIBITORS OF ADP-RIBOSE TRANSFERASES, CYCLASES, AND HYDROLASES, AND USES THEREOF  
Inventor: Anthony A. Sauvé and Vern L. Schramm  
Our File: 96700/725

Sir:

Enclosed please find the following documents for filing with the above-identified application in the names of Anthony A. Sauvé and Vern L. Schramm, entitled INHIBITORS OF ADP-RIBOSE TRANSFERASES, CYCLASES, AND HYDROLASES, AND USES THEREOF:

1. an Information Disclosure Statement By Applicant Form PTO/SB/08A with twenty-five (25) references attached; and
2. a Return receipt postcard.

Please acknowledge receipt of the enclosed documents by stamping the enclosed postcard and returning same.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN  
Attorneys for Applicants  
90 Park Avenue  
New York, New York 10016  
(212) 697-5995

Dated: New York, New York  
April 24, 2002

By:   
Elie H. Gendloff  
Registration No. 44,704

+

APR 24 2002

PTO/SB/084 (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

<b>Application Number</b>	10/038,760
<b>Filing Date</b>	January 4, 2002
<b>First Named Inventor</b>	Anthony A. Sauvé
<b>Group Art Unit</b>	1614
<b>Examiner Name</b>	to be assigned
<b>Attorney Docket Number</b>	96700/725

(use as many sheets as necessary)

Sheet	1	of	4	Attorney Docket Number	96700/725
-------	---	----	---	------------------------	-----------

[illegible][illegible]


Date	
Considered	

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



PTO/SB/08B (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known



Application Number	10/038,760
Filing Date	January 4, 2002
First Named Inventor	Anthony A. Sauvé
Group Art Unit	1614
Examiner Name	to be assigned
Attorney Docket Number	96700/725

TECH CENTER 1600/2900

APR 30 2002

RECEIVED

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	MEHTA, et al., The FASEB Journal, 10:1408-17, October 1996, "Human CD38, a cell-surface protein with multiple functions"	
	2	LEE, et al., J. Biol. Chem., 264:1608-15, January 1989, "Structural Determination of a Cyclic Metabolite of NAD <sup>+</sup> with Intracellular Ca <sup>2+</sup> -mobilizing Activity"	
	3	PRASAD, et al., Nat. Struct. Biol., 3:957-64, November 1996, "Crystal structure of Aplysia ADP ribosyl cyclase, a homologue of the bifunctional ectozyme CD38"	
	4	LEE, et al., Nature Struct. Biol., 1:143-44, March 1994, "The crystal structure of cyclic ADP-ribose"	
	5	REYES-HARDE, et al., Proc. Natl. Acad. Sci. USA, 96:4061-66, March 1999, "Evidence of a role for cyclic ADP-ribose in long-term synaptic depression in hippocampus"	
	6	GALIONE, et al., Science, 253:1143-46, September 1991, "Ca <sup>2+</sup> -Induced Ca <sup>2+</sup> Release in Sea Urchin Egg Homogenates: Modulation by Cyclic ADP-Ribose"	
	7	OKAMOTO H., Mol. Cell. Biochem., 193:115-18, March 1999, "The CD38-cyclic ADP-ribose signaling system in insulin secretion"	
	8	COCKAYNE, et al., Blood, 92:1324-33, August 1998, "Mice Deficient for the Ecto-Nicotinamide Adenine Dinucleotide Glycohydrolase CD38 Exhibit Altered Humoral Immune Responses"	
	9	SAUVÉ, et al., Biochemistry, 37:13239-49, September 1998, "The Reaction Mechanism for CD38. A Single Intermediate Is Responsible for Cyclization, Hydrolysis, and Base-Exchange Chemistries"	
	10	SAUVÉ, et al., J. Am. Chem Soc., 122:7855-59, August 2000, "A Covalent intermediate in CD38 Is Responsible for ADP-Ribosylation and Cyclization Reactions"	
	11	MULLER-STEFFNER, et al., J. Biol. Chem., 271:23967-72, September 1996, "Mechanism of Cyclization of Pyridine Nucleotides by Bovine Spleen NAD <sup>+</sup> Glycohydrolase"	

Examiner Signature

Date Considered

7/31/03


17 April 03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

### Complete if Known

Application Number	10/038,760
Filing Date	January 4, 2002
First Named Inventor	Anthony A. Sauvé
Group Art Unit	1614
Examiner Name	to be assigned
Attorney Docket Number	96700/725

RECEIVED  
APR 30 2002  
PTO CENTER 1600/2900

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>2</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>JS</i>	12	BERTHELIER, et al., Biochem. J., 330:1383-90, March 1998, "Human CD38 is an authentic NAD(P)+ glycohydrolase"	
	13	KIM, et al., Science, 261:1330-33, September 1993, "Synthesis and Degradation of Cyclic ADP-Ribose by NAD Glycohydrolases"	
	14	NIEDBALLA and VORBRÜGGEN, J. Org. Chem., 39:3654-60, December 1974, "A General Synthesis of N-Glycosides. I.1 Synthesis of Pyrimidine Nucleosides"	
	15	MORRISON and WALSH, Adv. Enzymol. Relat. Areas Mol. Biol., 61:201-301, 1988, "The Behavior and Significance of Slow-Binding Enzyme Inhibitors"	
	16	PORTER, et al., J. Biol. Chem., 270:15551-56, June 1995, "Identification of the Active Site Nucleophile in Nucleoside 2-Deoxyribosyltransferase as Glutamic Acid 98"	
	17	ZECHEL and WITHERS, Acc. Chem Res., 33:11-18, 2000, "Glycosidase Mechanisms: Anatomy of a Finely Tuned Catalyst"	
	18	WONG, et al., J. Biol. Chem., 273:34057-62, December 1998, "Identification of Glu-540 as the Catalytic Nucleophile of Human beta-Glucuronidase Using Electrospray Mass Spectrometry"	
	19	WITHERS and STREET, J. Am. Chem. Soc., 110:8551-53, December 1988, "Identification of a Covalent alpha-D-Glucopyranosyl Enzyme Intermediate Formed on a beta-Glucosidase"	
	20	MULLER-STEFFNER, et al., J. Biol. Chem., 267:9606-11, May 1992, "Slow-binding Inhibition of NAD+ Glycohydrolase by Arabino Analogues of beta-NAD+"	
	21	BERTHELIER, et al., Eur. J. Biochem., 267(10):3056-64, May 2000, "Probing ligand-induced conformational changes of human CD38"	
<i>JS</i>	22	MERKLER, et al., Biochemistry, 29:8358-64, September 1990, "The Rate Constant Describing Slow-Onset Inhibition of Yeast AMP Deaminase by Coformycin Analogues Is Independent of inhibitor Structure"	

Examiner Signature

*[Signature]* 7/31/03

Date

Considered

17 April 03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet	4	of	4
-------	---	----	---

**Complete if Known**

<b>Application Number</b>	10/038.760
<b>Filing Date</b>	January 4, 2002
<b>First Named Inventor</b>	Anthony A. Sauvé
Group Art Unit	1614
<b>Examiner Name</b>	to be assigned
<b>Attorney Docket Number</b>	96700/725

**CENTER 1600/2900**

APPENDIX 3

+ RECEIVED

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner  
Signature

Date  
Considered

17 April 03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**